An airport worker stands next to boxes of Moderna coronavirus vaccine, donated by the U.S. government via the COVAX facility, after their arrival at the airport in Nairobi, Kenya on Aug. 23, 2021. Moderna signed a memorandum of understanding with Kenya's government on Monday, March 7, 2022 for the drugmaker's first mRNA vaccine manufacturing facility in Africa, the company said. (AP Photo/Brian Inganga, File)NAIROBI, Kenya (AP) — Moderna signed a memorandum of understanding with Kenya’s government on Monday for the drugmaker’s first mRNA vaccine manufacturing facility in Africa, the company said.
The goal is to produce up to 500 million doses of vaccines a year for the African continent, Moderna said in a statement. The focus is on drug substance manufacturing, it said, though the facility could be expanded to include fill-and-finish work.
“In parallel, Moderna is also working on plans to allow it to fill doses of its COVID-19 vaccine in Africa as early as 2023, subject to demand,” the company said.
The COVID-19 pandemic highlighted the huge need for vaccine manufacturing on the African continent, which remains the least-vaccinated region in the world against the coronavirus. The continent relies on imports for about 99% of its vaccine needs, the World Health Organization has said.
Frustrated by richer nations’ vaccine hoarding, African leaders joined together to pursue the goal of bringing more vaccine manufacturing to the continent of 1.3 billion people.
In October, Senegal and Rwanda signed an agreement with BioNTech for the construction of its first start-to-finish factories to make messenger RNA vaccines in Africa.
The novel mRNA process uses the genetic code for the spike protein of the coronavirus and is thought to trigger a better immune response than traditional vaccines. Scientists hope the technology, which is easier to scale up than traditional vaccine methods, might ultimately be used to make vaccines against other diseases, including malaria.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
